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Aiming to increase the potency of synthetic long peptide (SLP)-based cancer vaccines, the Toll-like receptor 2 (TLR2)
ligand Pam3CSK4 was conjugated in a chemically deﬁned fashion to SLPs harbouring both cytotoxic T lymphocyte (CTL)
and T helper epitopes. We recently showed that these SLP-conjugates induce strong antitumor immunity in murine
cancer models.
Vaccines consisting of multiple over-
lapping synthetic long peptides (SLPs)
constitute a promising immunization
approach.1 SLP-based vaccines comprise
all potential CD4- and CD8-reactive epit-
opes within an antigen of choice for pre-
sentation with a wide range of HLA-
alleles. We have shown the efficacy of such
a vaccine, consisting of SLPs of HPV16
E6 and E7, in treating patients with pre-
malignant HPV16-induced vulvar intrae-
pithelial neoplasia (VIN).2 In this Phase II
trial, more than 50% of SLP vaccine-
treated patients experienced a complete or
partial regression of lesions. In contrast,
patients with advanced HPV16-induced
cervical lesions failed to exhibit clinically
relevant responses to the SLP vaccine,
although all patients displayed increased
blood frequencies of HPV-specific T cells
in peripheral blood, albeit at lower levels
than the complete responders in the VIN
study.3 Results from another trial in
patients with cervical premalignant lesions
indicated that the HPV16 SLP vaccine
induced T helper type 2 (Th2) T cell
responses long after vaccination,4 suggest-
ing the vaccine may be improved by the
addition of a T helper type 1 (Th1)-skewing
adjuvant.
We have previously shown that cova-
lent attachment of a synthetic Toll-like
receptor ligand (TLR-L) to an SLP in a
one-to-one stoichiometry improves the
efficacy of SLP vaccination in several
ways. Firstly, a TLR-L SLP conjugate has
been shown to be efficiently targeted to
TLR-expressing dendritic cells (DC) in
vivo.5 Secondly, the synthetic triacylated
lipoprotein and TLR2 ligand Pam3CSK4,
and oligonucleotide and TLR9 ligand
CpG, retained their DC maturation
capacity upon covalent conjugation to a
long peptide molecule, affecting expres-
sion of pro-inflammatory cytokines, up-
regulation of co-stimulatory molecules
and efficient cross-presentation by DCs.5
Furthermore, the ability of the TLR-L to
mature DCs has been shown to be essen-
tial in TLR-L SLP conjugate-mediated
priming of endogenous CD8C T cells
induced against a model antigen.6
Thirdly, we described the formation of an
antigen storage depot within matured
DCs upon uptake of conjugated SLP,
which allows for prolonged cross-presenta-
tion of MHC Class I epitopes.7 Taken
together, these properties explain the effi-
cacy of TLR-L SLP conjugates in our
recent vaccination study inducing antitu-
mor immunity against melanoma and
lymphoma in mice (see Fig. 1).
In our recent report,1 we set out to
determine the efficacy of different TLR2-
L SLP conjugates harbouring either
tumor-specific CTL or T helper epitopes
in a subcutaneous vaccination approach
in 2 aggressive murine tumor models.
The conjugated SLPs used in this study
were shown to induce robust T-cell acti-
vation in vitro and in vivo. T cells
exposed to DCs loaded with a TLR2-L
SLP conjugate in vitro produced more
Th1-type cytokines. Importantly, vacci-
nation with conjugated SLPs induced
more effective antitumor immunity than
the comparative mixture of SLPs and
equimolar amounts of TLR2-L. It was
estimated that the effective dose of con-
jugates was at least 50-fold lower than
that of the equivalent mixtures. Besides,
our data showed that the integration of
CD4C T cell epitopes in the vaccine
were essential for tumor control. Control
of the aggressive leukemia virus-induced
RMA lymphoma8 by CD4C T cell-
dependent immunity, could even be
achieved in the majority of mice with a
single dose of TLR2-L SLP conjugate
harbouring a CD4C T cell epitope. This
shows that TLR-L-SLP conjugates not
only support CTL priming by effective
processing through the MHC Class I
cross-presentation route but also enhan-
ces T helper cell priming by effective
MHC Class II peptide presentation.
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AUTHOR'S VIEW
TLR-ligands have received consider-
able attention to be incorporated into vac-
cination regimens as they bridge innate
signaling and adaptive immune
responses.9 Up to now, the TLR7-L imi-
quimod, the bacillus Calmette-Guerin
(BCG) and the vaccine adjuvant mono-
phosphoryl lipid A (MPL) are the only
TLR-ligands that are approved by the
Food and Drug Administration for use as
either standalone therapies or as a vaccine
adjuvant.10 We initiated studies on differ-
ent types of TLR-L SLP conjugates as
potential vaccines. In this setting, we
found that a small-molecule based TLR7-
L loses its potency to trigger its receptor
upon conjugation to an SLP.6 Contrary to
this, the TLR9-L CpG was successfully
conjugated to SLP with intact biological
activity, although it did not outperform
SLP conjugated to the TLR2-L
Pam3CSK4.
5 Besides, TLR9 is only selec-
tively expressed on human DC types and
is therefore less suitable for clinical transla-
tion. In view of manufacturing, conjugat-
ing nucleotide-based TLR-ligands is less
favorable than Pam3CSK4, which can be
N-terminally conjugated to the SLP pro-
duced by ‘in-line’ automatic peptide syn-
thesis. For future clinical studies we have
successfully synthesized TLR2-L SLP
conjugates of HPV16 E6 by this proce-
dure of good manufacturing procedure
(GMP) quality. These conjugates were
able to activate HPV16-E6 specific
patient-derived T cell clones (unpublished
data). In addition, we have further opti-
mized the potency of TLR2-L Pam3CSK4
by chemical modification,11 a variant that
we will further explore for clinical
applications.
In the coming years, a Phase I/II clini-
cal trial is planned to assess safety and
immunogenicity of optimized TLR2-L
SLP conjugates in patients with HPV-
induced cancer. A plethora of clinical
applications of these synthetic adjuvants
and therapeutic cancer vaccines can be
envisaged to further improve immuno-
therapy regimens. These may include
combination treatment with immuno-
modulatory drugs, such as ipilimumab
and nivolumab, application along with
Treg-depleting therapies, or together with
chemo- or radiotherapy. Recently, we
have observed decreased levels of myeloid
derived suppressor cells in advanced stage
cervical cancer patients after chemother-
apy, favoring SLP-vaccine induced T-cell
responses (unpublished observations).
The TLR-L conjugated SLP platform
by itself is very versatile and is amenable
to any antigen. Therefore, this novel
approach constitutes a step forward in per-
sonalized treatment, as SLPs of cancer-
and patient-specific epitopes and neoanti-
gens can readily be synthesized.
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Figure 1. Covalent attachment of adjuvants to long antigenic peptides results in improved immunological efﬁcacy of fully synthetic vaccines.
Biological and logistic advantages are indicated, including uptake, the ability to induce dendritic cell (DC) maturation and durability of presentation, all
of which impact enhanced T cell activation.
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